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I) Introduction 
Vitally important functions that can be exemplified 
by the protection of the mammalian fetus from 
rejection, are safeguarded by multiple mechanisms. 
This is also true for protection against tumor 
development. The vulnerability of our somatic cells 
to potentially carcinogenic noxae and the plethora of 
genetic and epigenetic changes that can favor the 
microevolution of a cell clone towards malignancy, 
would make us highly cancer prone in the absence of 
multiple defence systems. 
Traditionally, protection against cancer has been 
mainly if not exclusively ascribed to the immune 
system. The basic idea has been already expressed by 
Paul Ehrlich in 1909 (Ehrlich, 1909).  
He wrote that the complicated fetal and postfetal 
development must generate a large number of 
"aberrante Keime", translatable to "mutated cells". 
Were it not for the defense mechanisms of the 
organism, Ehrlich continued, cancer would arise in an 
"enormous frequency". 
II) Immune surveillance 
The hypothesis of immune surveillance was 
formulated by two prominent immunologists, Lewis 
Thomas in 1959 (Thomas, 1959) and Mac Farlane 
Burnet in 1964 (Burnet, 1971). In Burnet's words: "In 
large long lived animals....inheritable genetic changes 
must be common in somatic cells and a proportion of 
these changes will represent steps toward 
malignancy.  
It is an evolutionary necessity that there should be 
some mechanism for elimination or inactivity of such 
potentially dangerous mutant cells and it is postulated 
that this mechanism is of immunological character". 
The evolutionary necessity of cancer protection is 
certainly true, but the unique role attributed to the 
immune system ignores two salient facts: a) tumor 
evolution involves the loss rather than the gain of 
many functions, and b) the cancer cell phenotype is 
easily malleable.  
This does not augur well for the immune recognition 
of tumors as "non-self" targets. Even if adventitious, 
immunologically recognizable mutations would 
occur, they may be readily circumvented by further 
mutations or phenotypic modulation. There is one 
important exception, however. Oncogenic proteins of 
DNA tumor viruses such as SV40, polyoma, 
papilloma and EBV are readily recognized by the 
immune system as non-self. They are also relatively 
stable targets since their expression is a prerequisite 
for the proliferation of the virally transformed cell. In 
humans, the highly effective multicomponental 
protection against B cells that carry the highly 
transforming Epstein Barr virus (EBV) is a case in 
point. 
If the immune system cannot mount the robust 
immunity envisaged in the early statements of 
Ehrlich, Thomas and Burnet, it is still true that we are 
strongly protected against cancer development. It is
well established that the majority of tumor cells that 
disseminate during surgery do not give rise to 
metastasis. This is not necessarily an immune 
protection, however, as so frequently assumed. The 
well documented fact that dormant tumor cells can 
"wake up" years or decades later also speaks against 
immune killing. 
What other mechanisms protect us against cancer? 
There is evidence for at least four different types of 
"non immune surveillance" against cancer. Two of 
them, genetic (DNA repair and checkpoint control 
based) and intracellular (largely apoptosis related) 
surveillances are well established. Evidence for 
epigenetic surveillance, related to chromatin 
structure and particularly the stringency of 
imprinting, has only recently started to emerge. A 
fourth, already quite strong and rapidly increasing 
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area, intercellular surveillance, points to the 
importance of the tumor microenvironment. 
III) Genetic surveillance 
Tumor risk is highly influenced by mutations in genes 
that control the fidelity of DNA replication, the 
efficacy of DNA repair, and the checkpoint controls 
of chromosome separation. Mutations in these genes, 
whether identified as point mutations, microsatellit  
instability, or loss of heterozygosis, are referred to as 
mutator mutations. 
Xeroderma pigmentosum (XP) is the oldest known 
case of a specific DNA repair deficiency. It is due to 
recessive mutation in one of the essential components 
of the nucleotide excision repair (NER) system, the 
repairosome. The latter is composed of 30 different 
proteins, and its main function is to excise thymidine 
dimers from UV exposed DNA in the skin 
epithelium.  
XP patients must protect themselves from light all 
their lives, but they nevertheless develop multiple 
skin carcinomas. This points to the paramount 
importance of DNA repair as a first-line surveillance 
mechanism. 
Hereditary non polyposis colon cancer (HNPCC) is 
due to a defect in one of several DNA mismatch 
repair (MMR) genes. Some of their products can 
splice out the mismatched region and insert new 
bases to fill the gap. MMR defects can be manifested 
as microsatellite instability (MSI) and are associated 
with multiple cancers. MLH1 is one of the frequently 
involved genes. MLH1 mutation in the hereditary 
cases and epigenetic silencing by dense 
hypermethylation of the 5' promoter region in 
sporadic cases can lead to the same MSI phenotype. 
These and other examples have identified DNA repair 
as a robust protection mechanism against cancer. 
IV) Intracellular surveillance 
Growth arrest and/or programmed cell death are 
best known. The former may end in apoptosis or 
other types of cell death. Apoptosis is the endpoint f 
multi-pathway, multi-step programs that lead to the
enzymatic breakdown of cellular DNA. It can be 
initiated either through the extrinsic death receptor-
ligand or the intrinsic mitochondrial pathway (for a 
review see Klein, 2004). Most known programs 
converge towards the activation of caspases that 
cleave cellular substrates, leading to  
characteristic biochemical and morphological 
changes. There are also caspase independent 
pathways of apoptosis, however. The DNA damage 
response, capable of acting in very early precancerous 
lesions, is another case in point (reviewed in 
Höglund, 2006). 
In view of the multiple apoptotic pathways and the 
different levels where apoptosis can be triggered 
within each pathway, it may be asked whether there is 
a hierarchy between the different pathways. 
According to current consensus, inactivation events 
may occur in a stochastic fashion and the apparent 
choice between different inactivation pathways is due
to selection, depending on the cell type. A certain 
hierarchy among the pathways cannot be excluded, 
however and it appears that inactivation of the Rb and
p53 pathways could be a universal rule in neoplasia. 
V) Is there epigenetic 
surveillance? 
Several findings speak for an affirmative answer. The 
normally inactivated maternal allele of the IgF2 gene 
showed loss of imprinting (LOI) in about 10% of the 
normal human population (Cui et al., 2003). This LOI 
was associated with a 3.5-5 fold increase in the risk 
of colorectal adenoma development. This surprising 
finding has been corroborated in a mouse model 
system (Sakatani et al., 2005). Hybrid mice were 
generated by crossing two genetically engineered 
mouse strains. The females used for the cross were 
heterozygous for a deleted differentially methylated 
region (DMR). Inheritance of this deletion from the 
mother leads to the biallelic expression of IGF2 - 
corresponding to loss of imprinting. The males 
entering the hybrid cross were of the Min strain that 
carries a mutation in the adenomatous polyposis coli 
(APC) gene. APC mutations provide a strong 
predisposition to familial colonic polyposis, a 
precancerous condition in humans and mice. 
All hybrids derived from this cross carried the APC 
mutation, but only half of them inherited the 
imprinting defect. The frequency of intestinal 
adenomas was twice as high in the mice with the 
imprinting defect than in their littermate controls. 
Also, their intestinal crypts were longer and showed 
increased staining for proteins characteristic of 
intestinal-cell progenitors. Differentiation of the crypt 
cells to more specialized intestinal cell types was 
delayed. 
These observations show that the impairment of 
normal parental imprinting may interfere with cellular 
differentiation and thereby increase the probability of 
cancerous development.  
In more general terms, they suggest that cancer 
susceptibility may be influenced by differences in the
stringency of epigenetic control.  
This is consistent with earlier work showing that 
inbred mouse strains differ in the activity of enzymes 
involved in DNA methylation (Paz et al., 2002). 
VI) Intercellular surveillance 
This can also be referred to as microenvironmental 
control. A wide variety of observations fall into this 
category. The earliest experimental reports are basd 
on the contactual interaction between tumor and 
normal cells. Authors like Michael Stoker, Leo Sachs, 
Harry Rubin and others have shown already in the 
1960s, that admixture of normal to tumor cell 
suspensions can dramatically decrease the focus or 
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colony forming efficiency of the tumor cells. Cell 
contact is required for the effect. Recent studies have 
identified some of the junctions involved (for reviw 
see Glick and Yuspa, 2005). Adherence junctions 
play an important role. E-cadherin, a major structural 
component of the adherence junctions, is 
downregulated in most epithelial tumors, usually by 
promoter DNA methylation. Structural constituents of 
the adherence junctions, like catenins or connexins, 
are frequently mutated. Reestablishment of cadherin 
expression by transfection can revert the tumor 
phenotype. 
Other structural components of the tumor cell 
membrane may be involved in contactual control as 
well. β-integrins are often abnormally expressed by 
tumor cells. Antibody targeting of a rearranged, 
tumor associated β-integrin could inhibit tumor 
growth (Weaver et al., 1997). Notch receptors and 
their ligands regulate differentiation and proliferation. 
Their deletion in the basal layer of mouse epidermis 
leads to epidermal hyperplasia and skin tumor. Notch 
signaling between normal and pre-neoplastic cells can 
contribute to the suppression of the neoplastic 
phenotype (Glick and Yuspa, 2005). 
These and other contactual controls between normal 
and tumor cells may also explain the previously 
mentioned observation, that many disseminated 
tumor cells never grow into metastatic tumors. In one 
experimental model (Naumov et al., 2002), it was 
found that a significant fraction of injected mouse 
mammary tumor cells of either high or low metastatic 
potential persisted as solitary non dividing cells in the 
liver. Reinoculated to new hosts they were fully 
tumorigenic. Similar dormancy of solitary tumor cells 
has been observed with melanoma, squamous cell 
carcinoma and prostate carcinoma cells. The 
"awakening" of the dormant tumor cells may be 
accelerated by disturbing the tissue equilibrium e.g. 
by phorbol esters. 
The effects of the microenvironment on 
tumorigenicity are not restricted to contactual 
controls. Certain tumor cells can be induced to 
differentiate and loose tumorigenicity following 
their exposure to natural or non-natural signals. The 
most spectacular experiment in this category is the 
demonstration by Beatrice Mintz that cells of a highly 
malignant, but diploid teratoma could be 
"normalized" by implantation into early mouse 
embryos (Mintz and Illmensee, 1975). 
Microenvironmental structure may also exert a 
profound influence. Tumorigenic 2D cultures of 
mammary carcinoma cells could loose their 
tumorigenicity partly or completely, after they have 
been built into a 3D acinar structure in vitro (Nelson 
and Bissell, 2005). 
The tumor environment can thus influence the 
propensity of neoplastic cells to proliferate in vivo in 
a number of different ways. Some act by direct 
contact between tumor and normal cells, while others 
may act in a more distal, signal mediated fashion. 
VII) Own experiments 
As an experimental approach towards the study of the 
inhibition of tumor progression by the normal stroma, 
we have chosen to study the phenomenon of neighbor 
suppression, described by Stoker et al. (Stoker et al., 
1966). Our results so far obtained have been 
published in two papers (Flaberg et al., 2011; Flaberg 
et al., 2012). 
In the first study, the effect of 107 samples of low 
passage number primary normal fibroblasts from 
pediatric and adult donors was tested on the growth 
of six human tumor cell lines. The majority of the 
tested fibroblasts inhibited the proliferation of the 
tumor cells. The proliferation inhibiting effect ofthe 
fibroblasts differed, depending on the site of origin. 
Skin fibroblasts were more inhibitory than prostate 
fibroblasts, derived from donors with prostatic 
cancer. Normal hernia fibroblasts were less inhibitory 
than skin fibroblasts. 
Inhibition required direct cell contact. The inhibitory 
effect could also prevail across the mouse - human 
species barrier. 
The second study showed that effective inhibition 
requires the formation of a morphologically intact 
fibroblast monolayer before the seeding of the tumor 
cells. Interference with the formation of the 
monolayer impaired the inhibition.  
Telomerase immortalized human fibroblasts were 
good inhibitors. Based on morphological criteria, 
more and less inhibitory subclones could be selected 
from the telomerase immortalized line. 
Comparison of highly inhibitory and less inhibitory 
fibroblasts from the in vitro immortalized line and of 
inhibitory and less inhibitory ex vivo explants, 
identified a set of genes that co-segregated with the 
inhibitory phenotype.  
This was taken to suggest that our model system may 
reveal molecular mechanisms involved in contact 
mediated microenvironmental surveillance. 
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